Q&A: ‘Trial failure due to recruitment is a thing of the past thanks to AI’
CEO of H1 Ariel Katz’s mission is ‘to connect the world to the right doctor’ with a focus on connecting sponsors with the right PIs.
Spotlight
Latest news
Janssen’s NSCLC combo therapy meets primary endpoint in Phase III trial
The treatment of Rybrevant plus Lazertinib offered an improvement in progression-free survival in the trial.
29 September 2023
Aleta aims for pivotal US trial with CAR T-cell engager
Aleta hopes to initiate the registrational trial investigating ALETA-001 in B-cell malignancies in 2024/25.
29 September 2023
Ascletis reports positive data from Phase IIb hepatitis B therapy trial
Trial findings showed that 21.1% of subjects in the ASC22 group attained HBsAg loss, versus none in the placebo group.
29 September 2023
FDA approves IDE for HYDRAFIL system in degenerative disc disease study
ReGelTec aims to start enrolment in early 2024 for the trial evaluating its disc-mimicking hydrogel injecting system.
29 September 2023
ImmunoGenesis begins participant dosing in trial of IMGS‑001
The trial will evaluate the pharmacokinetics, safety and initial anti-tumour activity of IMGS-001.
29 September 2023
Synthekine doses first subject in Phase Ib of solid tumours trial
The trial will assess the safety, tolerability, pharmacokinetics, and anti-tumour activity of STK-012.
29 September 2023
Sensei doses first patient in combo therapy arm of trial for SNS-101
The company has fully enrolled the fourth cohort of the monotherapy arm at a dose of 10mg/kg.
29 September 2023
